Bladerunner - I'm not expecting any unexpected or major market moving info out of the upcoming CC, but I am looking forward to updates on Cortex's key areas:
-------------------------------------------------------
General comments on partnership talk status.
High impacts progress.
CX701 status.
Inlicensing status (hopefully on hold).
Hopefully that a PIPE is not planned or anticipated.
Hopefully clarification of the FDA's recent lifting of the CX717 dosing restrictions for AD and the applicability of that for the CX717 ADHD IND.
ADHD IND submission update, or even better announcement that it has happened.
AD trial status.
Mystery stuff?
-------------------------------------------------------
So each CC is useful for updates (which sometimes highlight opportunities for those who follow COR very closely) and also for picking up on anything that might have changed (timelines etc...).
It's also reassuring to hear that there has been constant progress in key areas such as High impacts development, and that there have been no setbacks.
Even nuances such as the general tone of the presentation are worth noting.
Market Data 
Markets 
AI
